A Single-arm, Open, Multicenter, Phase II Study of Famitinib as greater than or equal to Third Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC).
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Famitinib (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 16 Apr 2018 Status changed from recruiting to completed.
- 15 Jul 2011 New trial record